Double-blind placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease
Double-blind placebo-controlled study of metrifonate, an acetylcholinesterase inhibitor, for Alzheimer disease
复制标题
DOI：
10.1097/00002093-199601030-00003
复制
发表时间：
1996-09-01
影响因子：
2.1
通讯作者：
Vicari, S
中科院分区：
文献类型：
--
作者：
Becker, RE;Colliver, JA;Vicari, S
50名可能患有阿尔茨海默病（AD）的患者完成了为期3个月的双盲研究，以比较美曲膦酸钠和安慰剂。我们给药美曲磷酯以实现对红细胞乙酰胆碱酯酶活性40-60%的抑制。阿尔茨海默病评估量表认知子量表评分（ADAS-C）作为主要结局指标。治疗3个月后，美曲膦酸钠组ADAS-C评分与安慰剂组相比差异显著，差异为2.6分（g
Fifty patients with probable Alzheimer disease (AD) completed a 3-month double-blind study to compare metrifonate to placebo. We dosed metrifonate to achieve a 40-60% inhibition of red blood cell acetylcholinesterase activity. The Alzheimer Disease Assessment Scale cognitive subscale score (ADAS-C) served as the primary outcome measure. At the completion of 3 months of treatment, the metrifonate group ADAS-C score differed significantly from the placebo group score by 2.6 points (g